August 04, 2022
A California federal judge has granted lawyers with Robbins Geller Rudman & Dowd LLP more than $13.5 million in attorney fees along with final approval for a $54.2 million settlement for investors who alleged Puma Biotechnology Inc. misstated the effectiveness of a breast cancer treatment.
December 14, 2021
Investors alleging that Puma Biotechnology Inc. misstated the effectiveness of a breast cancer treatment, causing the biopharmaceutical company's share price to drop, asked a California federal judge Monday to preliminarily approve a $54.2 million proposed settlement, telling the judge the deal represents a complete recovery for the class.
July 29, 2019
Puma Biotechnology Inc. told a California federal judge last week that investors who scored a partial jury win on stock-drop claims are trying to breeze past the fact that the jury's verdict didn't resolve liability or damages.
February 05, 2019
A California federal jury has determined that Puma Biotechnology Inc. made misrepresentations in one of four contested statements about the results of a clinical trial involving a breast cancer treatment, awarding investors damages worth $4.50 per share.
January 23, 2018
Attorneys representing Puma Biotechnology Inc. in a class action suit brought by investors told the court Monday that it should allow them to film an attorney for the investors during a deposition of Puma's CEO, saying the attorney had been "disrespectful, unprofessional and abusive" in past depositions.
January 17, 2018
Camera-shy lawyers representing Puma Biotechnology Inc. investors on Tuesday asked a California federal judge to block a Latham & Watkins LLP defense team from training a video camera on them at an upcoming deposition.
December 11, 2017
A California federal judge on Friday granted class certification to Puma Biotechnologies Inc. investors in a stock drop suit accusing the company of misrepresenting the effectiveness of a breast cancer treatment called neratinib.
July 26, 2017
A California federal judge on Tuesday rejected a biotechnology company's request to dismiss an updated securities fraud lawsuit against it over allegedly misleading results in a clinical trial for its cancer drug, saying the new allegations clear the legal bar for stock-drop class actions.
March 15, 2017
Puma Biotechnology Inc. investors who lost money when clinical trial results undercut the biopharmaceutical company's prior statements about a cancer drug it was developing asked a California federal court Wednesday for class status and to have Robbins Geller Rudman & Dowd LLP represent them.
October 03, 2016
Puma Biotechnology Inc. will have to face a proposed class action for allegedly misleading investors about a breast cancer drug, a California federal judge ruled in an order Friday that also included some criticism for the way defense attorneys have employed judicial notice requests.